A Conconi1, C Lobetti-Bodoni2, S Montoto3, A Lopez-Guillermo4, R Coutinho4, J Matthews3, S Franceschetti5, F Bertoni6, A Moccia2, P M V Rancoita7, J Gribben3, F Cavalli2, G Gaidano5, T A Lister3, E Montserrat4, M Ghielmini2, E Zucca8. 1. Unit of Hematology, Department of Internal Medicine, Ospedale degli Infermi, Biella, Italy. 2. Oncology Institute of Southern Switzerland (IOSI), Ospedale San Giovanni, Bellinzona, Switzerland. 3. Barts Cancer Institute, Queen Mary University of London, London, UK. 4. Institute of Hematology and Oncology, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain. 5. Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont and AOU Maggiore della Carità, Novara, Italy. 6. Oncology Institute of Southern Switzerland (IOSI), Ospedale San Giovanni, Bellinzona, Switzerland Lymphoma and Genomics Research Program, Institute of Oncology Research (IOR), Bellinzona. 7. Lymphoma and Genomics Research Program, Institute of Oncology Research (IOR), Bellinzona Dalle Molle Institute for Artificial Intelligence (IDSIA), Manno-Lugano, Switzerland. 8. Oncology Institute of Southern Switzerland (IOSI), Ospedale San Giovanni, Bellinzona, Switzerland emanuele.zucca@eoc.ch.
Abstract
BACKGROUND: This study was aimed at investigating the clinical features and outcomes of follicular lymphoma (FL) patients younger than 40 years, which have not been extensively investigated yet. PATIENTS AND METHODS: One hundred and fifty-five patients younger than 40 years were retrospectively studied from a series of 1002 FL patients diagnosed in four different European Oncology Centres (Barcelona, Spain; Bellinzona, Switzerland; London, UK; Novara, Italy) from 1985 to 2010. RESULTS: Patients younger than 40 had a lower incidence of elevated LDH, high beta2-microglobulin, and a high-risk Follicular Lymphoma International Prognostic Index (FLIPI) score, whereas bone marrow involvement and bulky and disseminated lymphadenopathy were more frequent. At a median follow-up of 10 years, younger patients, in comparison with those older than 40, had significantly better overall (OS), cause-specific survival (CSS), and progression-free survival (PFS), with 10-year OS rate of 81% versus 51% (P < 0.0001), 10-year CSS rate of 82% versus 60% (P < 0.0001), and 10-year PFS of 39% versus 24% (P = 0.0098). However, there were no significant CSS and PFS differences in comparison with the patients aged 40-60. In multivariate analysis, having the lymphoma diagnosed in the last two decades and a favourable FLIPI score were associated with a significantly longer PFS and CSS in younger patients, whereas only FLIPI retained statistical significance for OS. CONCLUSIONS: In our series, FL patients younger than 40 have a median OS of 24 years and their outcome seems to be improving over time. However, they still have a significantly shorter life expectancy than that of an age-matched general healthy population.
BACKGROUND: This study was aimed at investigating the clinical features and outcomes of follicular lymphoma (FL) patients younger than 40 years, which have not been extensively investigated yet. PATIENTS AND METHODS: One hundred and fifty-five patients younger than 40 years were retrospectively studied from a series of 1002 FL patients diagnosed in four different European Oncology Centres (Barcelona, Spain; Bellinzona, Switzerland; London, UK; Novara, Italy) from 1985 to 2010. RESULTS:Patients younger than 40 had a lower incidence of elevated LDH, high beta2-microglobulin, and a high-risk Follicular Lymphoma International Prognostic Index (FLIPI) score, whereas bone marrow involvement and bulky and disseminated lymphadenopathy were more frequent. At a median follow-up of 10 years, younger patients, in comparison with those older than 40, had significantly better overall (OS), cause-specific survival (CSS), and progression-free survival (PFS), with 10-year OS rate of 81% versus 51% (P < 0.0001), 10-year CSS rate of 82% versus 60% (P < 0.0001), and 10-year PFS of 39% versus 24% (P = 0.0098). However, there were no significant CSS and PFS differences in comparison with the patients aged 40-60. In multivariate analysis, having the lymphoma diagnosed in the last two decades and a favourable FLIPI score were associated with a significantly longer PFS and CSS in younger patients, whereas only FLIPI retained statistical significance for OS. CONCLUSIONS: In our series, FL patients younger than 40 have a median OS of 24 years and their outcome seems to be improving over time. However, they still have a significantly shorter life expectancy than that of an age-matched general healthy population.
Authors: Niklas Gebauer; Britta Mengler; Svenja Kopelke; Alex Frydrychowicz; Alexander Fürschke; Carsten Hackenbroch; Arthur Bauer; Armin Riecke; Nikolaus von Bubnoff; Sebastian Fetscher; Hanno M Witte Journal: J Cancer Res Clin Oncol Date: 2021-08-20 Impact factor: 4.322
Authors: Mariano Provencio; Pilar Sabín; Jose Gomez-Codina; Maria Torrente; Virginia Calvo; Marta Llanos; Josep Gumá; Cristina Quero; Ana Blasco; Miguel Angel Cruz; David Aguiar; Francisco García-Arroyo; Javier Lavernia; Natividad Martinez; Manuel Morales; Alvaro Saez-Cusi; Delvys Rodriguez; Luis de la Cruz; Jose Javier Sanchez; Antonio Rueda Journal: PLoS One Date: 2017-05-11 Impact factor: 3.240
Authors: Matthew J Matasar; Stefano Luminari; Paul M Barr; Stefan K Barta; Alexey V Danilov; Brian T Hill; Tycel J Phillips; Mats Jerkeman; Massimo Magagnoli; Loretta J Nastoupil; Daniel O Persky; Jessica Okosun Journal: Oncologist Date: 2019-07-25